Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
40
MBOT Quote, Financials, Valuation and Earnings
Last price:
$0.97
Seasonality move
:
23.97%
Day range:
$0.96 - $1.00
52-week range:
$0.82 - $2.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.33x
Volume:
156.7K
Avg. volume:
191.8K
1-year change:
-28.35%
Market cap:
$16.5M
Revenue:
--
EPS (TTM):
-$0.80
Analysts' Opinion
-
Consensus RatingMicrobot Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Microbot Medical has an estimated upside of 618.32% from its current price of $0.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.97.
Fair Value
-
According to the consensus of 0 analysts, Microbot Medical has 618.32% upside to fair value with a price target of -- per share.
MBOT vs. S&P 500
-
Over the past 5 trading days, Microbot Medical has underperformed the S&P 500 by -0.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Microbot Medical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Microbot Medical revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Microbot Medical reported revenues of --.
Earnings Growth
-
Microbot Medical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Microbot Medical reported earnings per share of -$0.20.
Enterprise value:
12.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$14.2M | -$11M | -$10.5M | -$2.5M | -$3.3M | |
| EBITDA | -$14.1M | -$10.9M | -$10.4M | -$2.5M | -$3.3M | |
| Diluted EPS | -$1.97 | -$1.20 | -$0.80 | -$0.21 | -$0.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.9M | $18.8M | $6.6M | $8.4M | $5M | |
| Total Assets | $28M | $19.7M | $7.4M | $8.9M | $5.2M | |
| Current Liabilities | $919K | $1.4M | $1.7M | $1.5M | $1.4M | |
| Total Liabilities | $1.5M | $1.8M | $1.9M | $1.5M | $1.4M | |
| Total Equity | $26.5M | $17.9M | $5.5M | $7.4M | $3.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12M | -$9.2M | -$9M | -$1.7M | -$2.8M | |
| Cash From Investing | $2.9M | -$4.7M | $3M | -$2.6M | $140K | |
| Cash From Financing | -- | $10.9M | $5.1M | -$161K | $633K | |
| Free Cash Flow | -$12.1M | -$9.2M | -$9M | -$1.7M | -$2.8M | |
MBOT
Sector
Market Cap
$16.5M
$44.6M
Price % of 52-Week High
41.47%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-28.35%
-29.09%
Beta (5-Year)
1.619
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.99
200-day SMA
Sell
Level
$1.01
Bollinger Bands (100)
Buy
Level
0.91 - 1.01
Chaikin Money Flow
Sell
Level
-782.1M
20-day SMA
Sell
Level
$0.99
Relative Strength Index (RSI14)
Sell
Level
48.36
ADX Line
Sell
Level
10.74
Williams %R
Neutral
Level
-59.5996
50-day SMA
Sell
Level
$0.97
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
921M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.
Stock Forecast FAQ
In the current month, MBOT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MBOT average analyst price target in the past 3 months is --.
-
Where Will Microbot Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Microbot Medical share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Microbot Medical?
Analysts are divided on their view about Microbot Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Microbot Medical is a Sell and believe this share price will drop from its current level to --.
-
What Is Microbot Medical's Price Target?
The price target for Microbot Medical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MBOT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Microbot Medical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MBOT?
You can purchase shares of Microbot Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Microbot Medical shares.
-
What Is The Microbot Medical Share Price Today?
Microbot Medical was last trading at $0.97 per share. This represents the most recent stock quote for Microbot Medical. Yesterday, Microbot Medical closed at $0.97 per share.
-
How To Buy Microbot Medical Stock Online?
In order to purchase Microbot Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
